H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Cytokinetics to $56 from $29 and keeps a Buy rating on the shares. The analyst views the negative FDA panel vote as a "clearing event for investors." The news has paved the way for full focus now on aficamten, and what is "continuing differentiation" compared to Bristol Myers’ Camzyos, Pantginis tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics price target lowered to $29 from $75 at H.C. Wainwright
- Cytokinetics price target lowered to $71 from $82 at JMP Securities
- Cytokinetics (NASDAQ:CYTK) Stock Falls; Investors Disheartened by Heart Drug Problems
- Piper Sandler maintains that AdCom vote against Cytokinetics’ OM is a positive
- Cytokinetics falls 7% to $35.50 after resumption of trading